UNMC researchers are seeking to test a new RSV (Respiratory Syncytial Virus) vaccine named MVA-BN®-RSV. The study looks to discover whether the new vaccine will protect people from getting seriously ill from RSV. (IRB # 120-22-CB)
RSV is a virus that is contagious (spread from person to person) and can cause fever, coughing and other cold-like symptoms. Sometimes RSV can lead to serious respiratory illness. People 60 years of age or older are at risk for more severe illness if they contract RSV.
The RSV vaccine study will involve:
- Adults 65 years of age or older who
- Are willing and able to use a smartphone or tablet application to record information during the study.
The study will last for up to two years. In the first year, there is one in-person screening and vaccination visit with monthly phone call follow-ups. Subjects are required to complete questionnaires periodically and report respiratory symptoms twice a week on an application that is downloaded to their smartphone or tablet.
To get involved in the study, please contact the research team via email or call 402-836-9265.